Pacer Advisors Inc. boosted its position in Balchem Co. (NASDAQ:BCPC – Free Report) by 18.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,113 shares of the basic materials company’s stock after buying an additional 173 shares during the period. Pacer Advisors Inc.’s holdings in Balchem were worth $181,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Westside Investment Management Inc. acquired a new position in Balchem in the third quarter valued at $27,000. nVerses Capital LLC acquired a new position in Balchem in the third quarter valued at $35,000. Wilmington Savings Fund Society FSB acquired a new position in Balchem in the third quarter valued at $35,000. GAMMA Investing LLC lifted its holdings in Balchem by 73.4% in the third quarter. GAMMA Investing LLC now owns 841 shares of the basic materials company’s stock valued at $148,000 after buying an additional 356 shares during the period. Finally, Blue Trust Inc. lifted its holdings in Balchem by 642.5% in the third quarter. Blue Trust Inc. now owns 839 shares of the basic materials company’s stock valued at $148,000 after buying an additional 726 shares during the period. Institutional investors and hedge funds own 87.91% of the company’s stock.
Balchem Price Performance
Shares of NASDAQ BCPC opened at $163.39 on Wednesday. The firm’s 50-day moving average price is $166.19 and its 200-day moving average price is $170.43. Balchem Co. has a 1-year low of $137.69 and a 1-year high of $186.03. The firm has a market capitalization of $5.31 billion, a P/E ratio of 43.92, a P/E/G ratio of 4.30 and a beta of 0.69. The company has a current ratio of 2.98, a quick ratio of 1.90 and a debt-to-equity ratio of 0.21.
Balchem Increases Dividend
Analyst Ratings Changes
BCPC has been the topic of several recent analyst reports. StockNews.com upgraded shares of Balchem from a “hold” rating to a “buy” rating in a report on Monday, October 28th. HC Wainwright upped their price objective on shares of Balchem from $185.00 to $190.00 and gave the company a “buy” rating in a report on Monday, November 4th.
Check Out Our Latest Stock Report on BCPC
About Balchem
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Read More
- Five stocks we like better than Balchem
- What to Know About Investing in Penny Stocks
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- How Can Investors Benefit From After-Hours Trading
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- 3 Warren Buffett Stocks to Buy Now
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Want to see what other hedge funds are holding BCPC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Balchem Co. (NASDAQ:BCPC – Free Report).
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.